The biology of vascular endothelial growth factor

N Ferrara, T Davis-Smyth - Endocrine reviews, 1997 - academic.oup.com
Biology of Vascular Endothelial Growth Factor | Endocrine Reviews | Oxford Academic Skip to
Main Content Advertisement Oxford Academic Journals Books Search Menu Information …

Vascular endothelial growth factor (VEGF) and its receptors

G Neufeld, T Cohen, S Gengrinovitch… - The FASEB …, 1999 - Wiley Online Library
Vascular endothelial growth factor (VEGF) is a highly specific mitogen for vascular
endothelial cells. Five VEGF isoforms are generated as a result of alternative splicing from a …

Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis

CR Ozawa, A Banfi, NL Glazer… - The Journal of …, 2004 - Am Soc Clin Investig
Use of long-term constitutive expression of VEGF for therapeutic angiogenesis may be
limited by the growth of abnormal blood vessels and hemangiomas. We investigated the …

Angiogenesis in fracture repair

J Glowacki - Clinical Orthopaedics and Related Research®, 1998 - journals.lww.com
Fracture of bone disrupts its circulation and leads to necrosis and hypoxia of adjacent bone.
Under normal circumstances, fractured bone undergoes the orderly regeneration of its …

Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with …

TK Rosengart, LY Lee, SR Patel, TA Sanborn… - Circulation, 1999 - Am Heart Assoc
Background—Therapeutic angiogenesis, a new experimental strategy for the treatment of
vascular insufficiency, uses the administration of mediators known to induce vascular …

AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress

D Nagata, M Mogi, K Walsh - Journal of Biological Chemistry, 2003 - ASBMB
AMP-activated protein kinase (AMPK) is a stress-activated protein kinase that is regulated by
hypoxia and other cellular stresses that result in diminished cellular ATP levels. Here, we …

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene.

JR Gnarra, S Zhou, MJ Merrill… - Proceedings of the …, 1996 - National Acad Sciences
The VHL tumor suppressor gene is inactivated in patients with von Hippel-Lindau disease
and in most sporadic clear cell renal carcinomas. Although VHL protein function remains …

[PDF][PDF] Constitutive activation of NF-κB and T-cell leukemia/lymphoma in Notch3 transgenic mice

D Bellavia, AF Campese, E Alesse, A Vacca… - The EMBO …, 2000 - embopress.org
The multiplicity of Notch receptors raises the question of the contribution of specific isoforms
to T-cell development. Notch3 is expressed in CD4±8±thymocytes and is down-regulated …

Angiogenesis in ischemic heart disease

JA Ware, M Simons - Nature medicine, 1997 - nature.com
Angiogenesis in ischemic heart disease Page 1 TS 9 1997 Nature Publishing Group http://www.nature.com/naturemedicine
RIEVIEW Angiogenesis in ischemic heart disease Inducing the formation of new blood …

Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats

T Hayashi, K Abe, H Suzuki, Y Itoyama - Stroke, 1997 - Am Heart Assoc
Background and Purpose Vascular endothelial growth factor (VEGF) is a mitogen for
endothelial cells and also has the potential to increase vascular permeability. Therefore, it …